To Our Stockholders 2013 has been a year of considerable progress and achievement at Puma  with the rapid advancement of our Phase III and Phase II clinical programs  of PB272 (neratinib). We achieved a significant clinical milestone when  we reported strong top line results from the Phase II clinical trial of PB272  for the neoadjuvant treatment of breast cancer (I-SPY 2 TRIAL), and as a  result we look forward to the advancement of PB272 in this indication. We  believe we are well-positioned to aggressively advance and expand our  pipeline and meet our milestones in 2014 and beyond. It is a great pleasure  to reflect on our success and accomplishments. In June 2013, we achieved a significant milestone with the initiation of our  PhaseIIIclinicaltrialofPB272inpatientswithHER2-positivemetastaticbreast  cancer who have failed two or more prior treatments. This is a randomized  trial of PB272 plus Xeloda versus Tykerb plus Xeloda in patients with third-line HER2-positive metastatic breast cancer. This indication could  represent our first indication for PB272 in the treatment of HER2-positive  metastatic breast cancer. Based on preclinical and clinical data with PB272 in patients with activating  HER2 mutations, during 2013 Puma began several clinical trials of PB272 in  cancer patients with HER2 mutations. The first of these trials is a Puma-  sponsored study of PB272 in patients with HER2 mutated non-small cell  lung cancer, a trial in which patients are randomized to receive either PB272  alone or PB272 in combination with Torisel. We also continued to advance our clinical trial of PB272 in patients with  metastatic HER2-negative breast cancer who have a HER2 mutation. In this  investigator-sponsored trial, patients with metastatic disease are screened  for the presence of the HER2 mutation and if the mutation is present, the  patient is administered PB272 monotherapy. In October 2013, we also announced the initiation of a Phase II clinical  trial of PB272 as a single agent in patients with solid tumors who have  an activating HER2 mutation (basket trial). This Phase II basket trial  includes eight cohorts, or baskets, of patients, including (i) bladder/ urinary tract cancer; (ii) colorectal cancer; (iii) endometrial cancer; (iv)  Neratinib in HER2 Mutations Phase III Clinical Trial in HER2-Positive  Metastatic Breast Cancer